Lu Kang Pharmaceutical (600789.SH): The for the chemical raw material drug, Methanesulfonate Lenvatinib, has been approved.

Zhitong Finance APP reported that LuKang Pharmaceutical (600789.SH) announced that it has received the "Notice of Approval for the Marketing Application of Chemical Raw Drug" issued by the National Medical Products Administration regarding Lenvatinib Mesylate. The application for the drug's marketing has been approved. This medication is a receptor tyrosine kinase (RTK) inhibitor and is indicated for patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.